In this manner, application of the 3-biomarker prediction model to all patients with sepsis-induced hypotension may improve generalizability and time to sub-phenotype identification to facilitate future clinical trials without misclassification of patients with SP2. This evidence concerns the gene SP2 and Sepsis.